January 29-31 2019
Boston, MA
The 2ndAnnual DNA Damage Response Therapeutics Summit is the first industry-dedicated platform to advance DDR therapies across pharma and biotech.
Following the successful approval and commercialization of PARP inhibitors, there has been an increasing number of DNA damage response drugs moving into and advancing through the clinic. This industry focused summit will enable you to stay ahead of the game and understand how leading pharma and biotech decision makers are:
- Improving PARPi efficacy and overcoming resistance
- Targeting novel DNA repair pathways for DDR inhibitor monotherapies and combinations
- Broadening indication and patient population
- Refining patient selection with more predictive biomarkers
Pick the brains of 80+ senior industry peers from the likes of AstraZeneca, Tesaro, Pfizer, Repare Therapeutics, Ideaya, Abbvie, Celgene and many more, to help you tackle your challenges and improve your research strategy.
What to expect:
- 80+ Attendees
- 5+ hours of Networking
- 17 Expert Speakers
- 15 Case Studies
“This is a very informative meeting with the right experts and relevant topics.”
Tango Therapeutics
“Well organized and focused meeting covering all aspects of current challenges and achievements on synthetic lethal interactions.”
Mission Therapeutics
 |
 |